Peter Mourani
Concepts (429)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bronchopulmonary Dysplasia | 23 | 2021 | 69 | 6.840 |
Why?
| Hypertension, Pulmonary | 13 | 2023 | 126 | 4.070 |
Why?
| Intensive Care Units, Pediatric | 26 | 2023 | 186 | 3.040 |
Why?
| Heart Arrest | 14 | 2023 | 159 | 2.580 |
Why?
| Cardiopulmonary Resuscitation | 13 | 2023 | 137 | 2.540 |
Why?
| Respiration, Artificial | 17 | 2023 | 285 | 2.410 |
Why?
| Critical Illness | 22 | 2024 | 344 | 2.300 |
Why?
| Infant, Premature | 17 | 2021 | 335 | 2.260 |
Why?
| Pneumonia, Ventilator-Associated | 3 | 2021 | 22 | 2.080 |
Why?
| Child | 82 | 2024 | 7341 | 2.030 |
Why?
| Shock, Septic | 11 | 2023 | 80 | 2.020 |
Why?
| Sepsis | 12 | 2023 | 251 | 1.880 |
Why?
| Lung | 9 | 2024 | 507 | 1.790 |
Why?
| Prospective Studies | 40 | 2023 | 2604 | 1.780 |
Why?
| Respiratory Tract Infections | 5 | 2024 | 84 | 1.700 |
Why?
| Infant, Newborn | 39 | 2022 | 2907 | 1.640 |
Why?
| Respiratory Insufficiency | 5 | 2021 | 127 | 1.630 |
Why?
| Trachea | 3 | 2017 | 51 | 1.570 |
Why?
| Vascular Diseases | 5 | 2020 | 77 | 1.360 |
Why?
| Infant | 40 | 2023 | 3817 | 1.290 |
Why?
| Humans | 120 | 2024 | 54284 | 1.270 |
Why?
| Critical Care | 6 | 2021 | 234 | 1.260 |
Why?
| Influenza, Human | 9 | 2023 | 120 | 1.250 |
Why?
| Premature Birth | 4 | 2021 | 154 | 1.170 |
Why?
| Ventricular Dysfunction, Right | 3 | 2022 | 32 | 1.120 |
Why?
| Heart Ventricles | 2 | 2021 | 271 | 1.110 |
Why?
| Child, Preschool | 32 | 2022 | 4147 | 1.080 |
Why?
| Intensive Care Units | 8 | 2023 | 231 | 1.020 |
Why?
| RNA, Ribosomal, 16S | 4 | 2021 | 106 | 0.970 |
Why?
| Echocardiography | 7 | 2021 | 392 | 0.960 |
Why?
| Ventricular Function, Right | 2 | 2021 | 45 | 0.930 |
Why?
| Respiratory Syncytial Virus Infections | 3 | 2019 | 37 | 0.880 |
Why?
| Tobacco Smoke Pollution | 1 | 2023 | 56 | 0.860 |
Why?
| Intubation, Intratracheal | 3 | 2019 | 130 | 0.850 |
Why?
| Male | 53 | 2023 | 27334 | 0.820 |
Why?
| Female | 56 | 2023 | 28441 | 0.810 |
Why?
| Adolescent | 33 | 2023 | 6897 | 0.780 |
Why?
| Risk Factors | 20 | 2022 | 3935 | 0.750 |
Why?
| Patient Discharge | 10 | 2023 | 353 | 0.690 |
Why?
| Respiratory Tract Diseases | 1 | 2019 | 29 | 0.680 |
Why?
| Gestational Age | 7 | 2021 | 435 | 0.650 |
Why?
| Lung Diseases | 2 | 2010 | 86 | 0.640 |
Why?
| Echocardiography, Doppler | 3 | 2018 | 61 | 0.630 |
Why?
| Nutritional Support | 1 | 2017 | 35 | 0.630 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 38 | 0.620 |
Why?
| Retrospective Studies | 25 | 2023 | 6432 | 0.610 |
Why?
| Nitric Oxide | 6 | 2022 | 298 | 0.610 |
Why?
| Coinfection | 3 | 2022 | 34 | 0.600 |
Why?
| Bacteria | 4 | 2022 | 258 | 0.600 |
Why?
| Energy Intake | 1 | 2017 | 196 | 0.580 |
Why?
| Respiratory Syncytial Viruses | 2 | 2013 | 16 | 0.570 |
Why?
| Patient Readmission | 2 | 2018 | 242 | 0.540 |
Why?
| Echocardiography, Doppler, Pulsed | 1 | 2015 | 10 | 0.540 |
Why?
| Energy Metabolism | 1 | 2017 | 311 | 0.530 |
Why?
| Oxygen Inhalation Therapy | 1 | 2015 | 16 | 0.520 |
Why?
| Myocardial Contraction | 1 | 2015 | 116 | 0.510 |
Why?
| Aftercare | 4 | 2022 | 81 | 0.510 |
Why?
| Pulmonary Artery | 3 | 2011 | 151 | 0.500 |
Why?
| Chlorides | 3 | 2020 | 58 | 0.500 |
Why?
| Practice Guidelines as Topic | 1 | 2017 | 492 | 0.490 |
Why?
| Venous Thromboembolism | 2 | 2012 | 75 | 0.490 |
Why?
| Metapneumovirus | 1 | 2013 | 5 | 0.480 |
Why?
| Paramyxoviridae Infections | 1 | 2013 | 4 | 0.480 |
Why?
| Natriuretic Peptide, Brain | 1 | 2014 | 25 | 0.480 |
Why?
| Infant, Extremely Low Birth Weight | 1 | 2014 | 30 | 0.480 |
Why?
| Ventricular Function, Left | 1 | 2015 | 181 | 0.480 |
Why?
| Oxygen | 3 | 2019 | 361 | 0.470 |
Why?
| Ventricular Dysfunction, Left | 2 | 2020 | 98 | 0.470 |
Why?
| Pulmonary Embolism | 2 | 2012 | 106 | 0.460 |
Why?
| Bacterial Infections | 3 | 2023 | 105 | 0.460 |
Why?
| Peripheral Vascular Diseases | 1 | 2013 | 24 | 0.460 |
Why?
| Cohort Studies | 13 | 2022 | 1543 | 0.440 |
Why?
| Quality Improvement | 3 | 2022 | 245 | 0.440 |
Why?
| Acute Kidney Injury | 4 | 2021 | 403 | 0.440 |
Why?
| Quality of Life | 11 | 2023 | 922 | 0.430 |
Why?
| Bereavement | 2 | 2021 | 8 | 0.410 |
Why?
| Influenza A virus | 3 | 2020 | 18 | 0.410 |
Why?
| Denys-Drash Syndrome | 1 | 2011 | 3 | 0.410 |
Why?
| Wilms Tumor | 1 | 2011 | 17 | 0.400 |
Why?
| Embolectomy | 1 | 2011 | 15 | 0.400 |
Why?
| Vasodilator Agents | 3 | 2021 | 111 | 0.400 |
Why?
| Milrinone | 2 | 2021 | 10 | 0.380 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 88 | 0.360 |
Why?
| Logistic Models | 6 | 2019 | 995 | 0.360 |
Why?
| Kidney Neoplasms | 1 | 2011 | 196 | 0.350 |
Why?
| Follow-Up Studies | 8 | 2021 | 2387 | 0.350 |
Why?
| Water-Electrolyte Imbalance | 2 | 2020 | 17 | 0.340 |
Why?
| Administration, Inhalation | 5 | 2022 | 119 | 0.340 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2008 | 27 | 0.340 |
Why?
| Sulfones | 1 | 2008 | 24 | 0.340 |
Why?
| Pregnancy | 9 | 2022 | 2620 | 0.340 |
Why?
| Infant, Extremely Premature | 2 | 2020 | 31 | 0.330 |
Why?
| Coronary Care Units | 2 | 2018 | 8 | 0.330 |
Why?
| Multiple Organ Failure | 3 | 2023 | 56 | 0.330 |
Why?
| Anti-Bacterial Agents | 4 | 2024 | 820 | 0.330 |
Why?
| Heart Diseases | 2 | 2023 | 237 | 0.320 |
Why?
| Hernia, Diaphragmatic | 1 | 2008 | 22 | 0.320 |
Why?
| Health Resources | 4 | 2022 | 80 | 0.320 |
Why?
| Longitudinal Studies | 4 | 2020 | 746 | 0.320 |
Why?
| Time Factors | 9 | 2020 | 3213 | 0.320 |
Why?
| Piperazines | 1 | 2008 | 116 | 0.310 |
Why?
| Metagenomics | 4 | 2023 | 38 | 0.310 |
Why?
| Staphylococcal Infections | 2 | 2022 | 300 | 0.310 |
Why?
| Staphylococcus | 2 | 2017 | 33 | 0.310 |
Why?
| Hospital Mortality | 8 | 2023 | 465 | 0.300 |
Why?
| Length of Stay | 4 | 2020 | 683 | 0.290 |
Why?
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 302 | 0.290 |
Why?
| Age Factors | 6 | 2021 | 1198 | 0.280 |
Why?
| Parents | 4 | 2021 | 344 | 0.280 |
Why?
| United States | 11 | 2022 | 5217 | 0.280 |
Why?
| Wounds and Injuries | 2 | 2021 | 321 | 0.280 |
Why?
| Young Adult | 9 | 2022 | 4318 | 0.270 |
Why?
| Muscle, Smooth, Vascular | 2 | 2004 | 140 | 0.270 |
Why?
| Treatment Outcome | 11 | 2022 | 5604 | 0.260 |
Why?
| Diastole | 3 | 2019 | 79 | 0.250 |
Why?
| Ribosomal Protein S6 | 1 | 2004 | 1 | 0.250 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2004 | 29 | 0.240 |
Why?
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 19 | 0.240 |
Why?
| Heart Failure | 2 | 2021 | 541 | 0.240 |
Why?
| Epinephrine | 2 | 2022 | 97 | 0.240 |
Why?
| Tunica Intima | 1 | 2004 | 52 | 0.240 |
Why?
| Caregivers | 3 | 2021 | 241 | 0.240 |
Why?
| Receptors, Immunologic | 2 | 2022 | 37 | 0.240 |
Why?
| Adult | 10 | 2024 | 14207 | 0.240 |
Why?
| Myocytes, Smooth Muscle | 1 | 2004 | 92 | 0.230 |
Why?
| Protein Kinases | 1 | 2004 | 89 | 0.230 |
Why?
| Genetic Predisposition to Disease | 3 | 2019 | 570 | 0.230 |
Why?
| Cotinine | 1 | 2023 | 23 | 0.230 |
Why?
| Smoke | 1 | 2023 | 20 | 0.230 |
Why?
| Proto-Oncogene Proteins | 1 | 2004 | 169 | 0.230 |
Why?
| Colorado | 4 | 2017 | 15 | 0.230 |
Why?
| Pneumonia, Staphylococcal | 1 | 2022 | 7 | 0.220 |
Why?
| Hypotension | 1 | 2023 | 67 | 0.220 |
Why?
| Socioeconomic Factors | 3 | 2020 | 642 | 0.220 |
Why?
| Respiratory Syncytial Virus, Human | 1 | 2022 | 6 | 0.220 |
Why?
| Meconium Aspiration Syndrome | 1 | 2022 | 3 | 0.210 |
Why?
| Hospitalization | 4 | 2023 | 705 | 0.210 |
Why?
| Reproducibility of Results | 4 | 2020 | 1304 | 0.210 |
Why?
| Pregnancy in Diabetics | 1 | 2022 | 25 | 0.210 |
Why?
| Communicable Diseases | 1 | 2022 | 58 | 0.210 |
Why?
| Shock | 1 | 2022 | 37 | 0.210 |
Why?
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 38 | 0.210 |
Why?
| Multivariate Analysis | 4 | 2018 | 643 | 0.210 |
Why?
| Central Venous Catheters | 1 | 2022 | 31 | 0.210 |
Why?
| Extremities | 1 | 2021 | 27 | 0.200 |
Why?
| Diabetes, Gestational | 1 | 2022 | 54 | 0.200 |
Why?
| Multiple Trauma | 1 | 2021 | 34 | 0.200 |
Why?
| Blood Pressure | 4 | 2023 | 587 | 0.200 |
Why?
| Iloprost | 1 | 2021 | 4 | 0.200 |
Why?
| Central Venous Pressure | 1 | 2021 | 8 | 0.200 |
Why?
| Prone Position | 1 | 2021 | 38 | 0.200 |
Why?
| Abdominal Injuries | 1 | 2021 | 34 | 0.200 |
Why?
| Epoprostenol | 1 | 2021 | 27 | 0.200 |
Why?
| Spinal Injuries | 1 | 2021 | 21 | 0.200 |
Why?
| Pulmonary Circulation | 2 | 2015 | 36 | 0.200 |
Why?
| Capnography | 1 | 2021 | 17 | 0.200 |
Why?
| Patient Positioning | 1 | 2021 | 35 | 0.200 |
Why?
| Thoracic Injuries | 1 | 2021 | 35 | 0.200 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 206 | 0.200 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2021 | 62 | 0.200 |
Why?
| Pneumonia | 1 | 2022 | 129 | 0.190 |
Why?
| Research Design | 3 | 2020 | 374 | 0.190 |
Why?
| Proteomics | 3 | 2020 | 343 | 0.190 |
Why?
| Catheterization, Central Venous | 1 | 2022 | 98 | 0.190 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 55 | 0.190 |
Why?
| Nervous System Diseases | 1 | 2022 | 97 | 0.190 |
Why?
| Radiography, Thoracic | 1 | 2021 | 69 | 0.190 |
Why?
| Vasopressins | 1 | 2021 | 42 | 0.190 |
Why?
| Angiogenic Proteins | 1 | 2020 | 7 | 0.190 |
Why?
| Morbidity | 4 | 2022 | 149 | 0.180 |
Why?
| Medicine | 1 | 2020 | 58 | 0.180 |
Why?
| Medical Audit | 1 | 2020 | 23 | 0.180 |
Why?
| Chronic Disease | 3 | 2022 | 614 | 0.180 |
Why?
| Cardiac Surgical Procedures | 1 | 2023 | 318 | 0.180 |
Why?
| Muscular Dystrophy, Duchenne | 1 | 2020 | 15 | 0.180 |
Why?
| Academic Medical Centers | 2 | 2017 | 141 | 0.180 |
Why?
| Toll-Like Receptor 4 | 1 | 2020 | 51 | 0.180 |
Why?
| Medical Records | 1 | 2020 | 92 | 0.180 |
Why?
| Severity of Illness Index | 5 | 2020 | 1084 | 0.180 |
Why?
| Mannose-Binding Lectin | 1 | 2019 | 3 | 0.180 |
Why?
| Motivation | 1 | 2021 | 291 | 0.170 |
Why?
| Signal Transduction | 2 | 2020 | 1753 | 0.170 |
Why?
| Tertiary Care Centers | 1 | 2019 | 83 | 0.170 |
Why?
| Drug Resistance, Bacterial | 1 | 2019 | 81 | 0.170 |
Why?
| Mothers | 2 | 2022 | 247 | 0.170 |
Why?
| Respiratory System | 1 | 2018 | 28 | 0.170 |
Why?
| Hyperglycemia | 1 | 2019 | 84 | 0.170 |
Why?
| Cardiotonic Agents | 1 | 2019 | 95 | 0.170 |
Why?
| Mutation, Missense | 1 | 2019 | 117 | 0.170 |
Why?
| Cardiopulmonary Bypass | 1 | 2018 | 97 | 0.160 |
Why?
| Fibroblasts | 1 | 2020 | 386 | 0.160 |
Why?
| Medical Staff, Hospital | 1 | 2018 | 19 | 0.160 |
Why?
| MicroRNAs | 1 | 2022 | 386 | 0.160 |
Why?
| Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 3 | 0.160 |
Why?
| Inservice Training | 1 | 2018 | 41 | 0.160 |
Why?
| Calorimetry, Indirect | 1 | 2017 | 29 | 0.160 |
Why?
| Glasgow Coma Scale | 3 | 2022 | 48 | 0.160 |
Why?
| Chorioamnionitis | 1 | 2017 | 21 | 0.160 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 206 | 0.160 |
Why?
| Fetal Membranes, Premature Rupture | 1 | 2017 | 23 | 0.150 |
Why?
| Intensive Care Units, Neonatal | 1 | 2018 | 117 | 0.150 |
Why?
| Renal Replacement Therapy | 1 | 2018 | 45 | 0.150 |
Why?
| Metabolomics | 1 | 2018 | 149 | 0.150 |
Why?
| Delirium | 1 | 2018 | 52 | 0.150 |
Why?
| Infant, Very Low Birth Weight | 1 | 2017 | 47 | 0.150 |
Why?
| Hypoglycemic Agents | 1 | 2019 | 177 | 0.150 |
Why?
| Computational Biology | 1 | 2019 | 231 | 0.150 |
Why?
| Tandem Mass Spectrometry | 1 | 2018 | 248 | 0.150 |
Why?
| Physicians | 1 | 2021 | 247 | 0.150 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2018 | 377 | 0.150 |
Why?
| Pre-Eclampsia | 1 | 2017 | 56 | 0.150 |
Why?
| Risk Assessment | 5 | 2018 | 1361 | 0.150 |
Why?
| Respiratory Distress Syndrome, Newborn | 1 | 2017 | 53 | 0.150 |
Why?
| Needs Assessment | 1 | 2017 | 154 | 0.150 |
Why?
| Observer Variation | 1 | 2017 | 138 | 0.150 |
Why?
| Hypertension | 2 | 2019 | 564 | 0.140 |
Why?
| Delphi Technique | 3 | 2020 | 38 | 0.140 |
Why?
| Infant, Low Birth Weight | 2 | 2015 | 75 | 0.140 |
Why?
| Birth Weight | 1 | 2017 | 126 | 0.140 |
Why?
| RNA-Binding Proteins | 1 | 2017 | 136 | 0.140 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2021 | 394 | 0.140 |
Why?
| Smoking | 2 | 2018 | 556 | 0.140 |
Why?
| Patient Care Team | 1 | 2018 | 273 | 0.140 |
Why?
| Pneumonia, Viral | 1 | 2019 | 184 | 0.140 |
Why?
| Endothelium-Dependent Relaxing Factors | 1 | 2015 | 4 | 0.140 |
Why?
| Organ Dysfunction Scores | 3 | 2020 | 17 | 0.140 |
Why?
| Blood Glucose | 2 | 2019 | 489 | 0.140 |
Why?
| Hospitals, Pediatric | 3 | 2023 | 272 | 0.140 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2017 | 173 | 0.130 |
Why?
| Trauma Centers | 3 | 2022 | 218 | 0.130 |
Why?
| Incidence | 2 | 2018 | 1082 | 0.130 |
Why?
| Indiana | 1 | 2015 | 16 | 0.130 |
Why?
| Medical Informatics | 1 | 2016 | 55 | 0.130 |
Why?
| Diabetic Ketoacidosis | 1 | 2014 | 18 | 0.130 |
Why?
| Hypokalemia | 1 | 2014 | 12 | 0.130 |
Why?
| Membrane Proteins | 1 | 2017 | 389 | 0.130 |
Why?
| Hemodynamics | 2 | 2023 | 290 | 0.120 |
Why?
| Schools, Medical | 1 | 2015 | 82 | 0.120 |
Why?
| Bronchiolitis, Viral | 1 | 2013 | 6 | 0.120 |
Why?
| Risk | 2 | 2012 | 343 | 0.120 |
Why?
| Tomography, X-Ray Computed | 1 | 2019 | 1213 | 0.120 |
Why?
| Influenza Vaccines | 1 | 2014 | 42 | 0.120 |
Why?
| Nasopharynx | 2 | 2023 | 32 | 0.110 |
Why?
| Fibrin Fibrinogen Degradation Products | 1 | 2012 | 11 | 0.110 |
Why?
| Cerebral Arterial Diseases | 1 | 2012 | 8 | 0.110 |
Why?
| Vitamin D | 1 | 2013 | 101 | 0.110 |
Why?
| Blood Coagulation Disorders | 1 | 2012 | 37 | 0.110 |
Why?
| Ultrasonography | 1 | 2015 | 480 | 0.110 |
Why?
| Antiphospholipid Syndrome | 1 | 2012 | 7 | 0.110 |
Why?
| Heart Defects, Congenital | 1 | 2018 | 608 | 0.110 |
Why?
| Anticoagulants | 2 | 2012 | 270 | 0.110 |
Why?
| Anti-Infective Agents | 1 | 2013 | 110 | 0.110 |
Why?
| Enoxaparin | 1 | 2012 | 25 | 0.110 |
Why?
| Pediatrics | 1 | 2016 | 323 | 0.110 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 1604 | 0.110 |
Why?
| Antihypertensive Agents | 1 | 2013 | 139 | 0.110 |
Why?
| Immunomodulation | 1 | 2012 | 42 | 0.110 |
Why?
| Polysaccharides | 1 | 2012 | 57 | 0.100 |
Why?
| Fetal Blood | 1 | 2012 | 67 | 0.100 |
Why?
| RNA, Ribosomal | 1 | 2011 | 18 | 0.100 |
Why?
| Bacterial Load | 1 | 2011 | 13 | 0.100 |
Why?
| Abbreviated Injury Scale | 2 | 2021 | 7 | 0.100 |
Why?
| Interferons | 2 | 2022 | 44 | 0.100 |
Why?
| Survival Rate | 3 | 2019 | 951 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2019 | 923 | 0.100 |
Why?
| Suction | 1 | 2011 | 22 | 0.100 |
Why?
| Grief | 2 | 2021 | 9 | 0.100 |
Why?
| Pressure | 2 | 2023 | 120 | 0.100 |
Why?
| RNA, Bacterial | 1 | 2011 | 58 | 0.100 |
Why?
| Fibrinolytic Agents | 1 | 2012 | 139 | 0.100 |
Why?
| Postoperative Complications | 1 | 2018 | 1033 | 0.100 |
Why?
| Fatal Outcome | 1 | 2012 | 225 | 0.100 |
Why?
| Metagenome | 1 | 2011 | 44 | 0.100 |
Why?
| Survivors | 2 | 2022 | 137 | 0.100 |
Why?
| Stem Cells | 1 | 2012 | 193 | 0.100 |
Why?
| Drug Administration Schedule | 1 | 2011 | 401 | 0.100 |
Why?
| Phenotype | 2 | 2023 | 820 | 0.090 |
Why?
| Transcriptome | 2 | 2023 | 346 | 0.090 |
Why?
| Intensive Care, Neonatal | 1 | 2010 | 24 | 0.090 |
Why?
| Stroke Volume | 2 | 2021 | 150 | 0.090 |
Why?
| Prognosis | 3 | 2018 | 2118 | 0.090 |
Why?
| Clinical Competence | 2 | 2023 | 446 | 0.090 |
Why?
| Gene Expression | 2 | 2022 | 664 | 0.080 |
Why?
| Cytokines | 1 | 2012 | 676 | 0.080 |
Why?
| Purines | 1 | 2008 | 45 | 0.080 |
Why?
| Diseases in Twins | 1 | 2008 | 15 | 0.080 |
Why?
| Pulmonary Edema | 1 | 2008 | 17 | 0.080 |
Why?
| Pulmonary Wedge Pressure | 1 | 2008 | 26 | 0.080 |
Why?
| Survival Analysis | 2 | 2022 | 735 | 0.080 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 673 | 0.080 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2022 | 552 | 0.070 |
Why?
| Stroke | 1 | 2012 | 526 | 0.070 |
Why?
| Cardiovascular Diseases | 1 | 2012 | 476 | 0.070 |
Why?
| Neovascularization, Physiologic | 2 | 2012 | 72 | 0.070 |
Why?
| Cell Division | 2 | 2004 | 330 | 0.070 |
Why?
| Aorta | 2 | 2004 | 177 | 0.070 |
Why?
| Cardiac Catheterization | 1 | 2008 | 258 | 0.070 |
Why?
| RNA, Viral | 2 | 2017 | 141 | 0.070 |
Why?
| Culture Media, Serum-Free | 1 | 2004 | 20 | 0.060 |
Why?
| Vascular Resistance | 1 | 2004 | 60 | 0.060 |
Why?
| Androstadienes | 1 | 2004 | 9 | 0.060 |
Why?
| Carotid Artery Injuries | 1 | 2004 | 14 | 0.060 |
Why?
| Chromones | 1 | 2004 | 16 | 0.060 |
Why?
| Oligonucleotides, Antisense | 1 | 2004 | 29 | 0.060 |
Why?
| Respiratory Function Tests | 1 | 2004 | 98 | 0.060 |
Why?
| Hyperoxia | 1 | 2004 | 26 | 0.060 |
Why?
| Probability | 1 | 2004 | 176 | 0.060 |
Why?
| Drug Resistance, Microbial | 1 | 2024 | 51 | 0.060 |
Why?
| Glycocalyx | 1 | 2023 | 3 | 0.060 |
Why?
| Heparitin Sulfate | 1 | 2023 | 10 | 0.060 |
Why?
| Morpholines | 1 | 2004 | 64 | 0.060 |
Why?
| PTEN Phosphohydrolase | 1 | 2004 | 61 | 0.060 |
Why?
| Disaccharides | 1 | 2023 | 12 | 0.060 |
Why?
| Chondroitin Sulfates | 1 | 2023 | 15 | 0.060 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 12 | 0.060 |
Why?
| Animals | 5 | 2020 | 14385 | 0.060 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2004 | 85 | 0.060 |
Why?
| Syndecan-1 | 1 | 2023 | 82 | 0.060 |
Why?
| Sirolimus | 1 | 2004 | 65 | 0.060 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 75 | 0.060 |
Why?
| Catheterization | 1 | 2004 | 108 | 0.060 |
Why?
| Water-Electrolyte Balance | 1 | 2023 | 40 | 0.060 |
Why?
| Proteoglycans | 1 | 2023 | 96 | 0.060 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 176 | 0.060 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 153 | 0.060 |
Why?
| Carbon Dioxide | 1 | 2023 | 102 | 0.060 |
Why?
| Chemotactic Factors | 1 | 2022 | 8 | 0.060 |
Why?
| Sequence Analysis, RNA | 1 | 2023 | 107 | 0.060 |
Why?
| Methicillin | 1 | 2022 | 9 | 0.060 |
Why?
| Sodium Bicarbonate | 1 | 2022 | 9 | 0.050 |
Why?
| Protein Processing, Post-Translational | 1 | 2004 | 183 | 0.050 |
Why?
| Rats, Sprague-Dawley | 2 | 2004 | 1663 | 0.050 |
Why?
| Case-Control Studies | 2 | 2019 | 1228 | 0.050 |
Why?
| Haemophilus influenzae | 1 | 2022 | 21 | 0.050 |
Why?
| Adaptive Immunity | 1 | 2022 | 39 | 0.050 |
Why?
| Phosphorylation | 1 | 2004 | 614 | 0.050 |
Why?
| Protein Kinase Inhibitors | 1 | 2004 | 216 | 0.050 |
Why?
| Hospitals | 1 | 2023 | 188 | 0.050 |
Why?
| Interferon-gamma | 1 | 2022 | 195 | 0.050 |
Why?
| Norepinephrine | 1 | 2022 | 119 | 0.050 |
Why?
| Adrenal Cortex Hormones | 1 | 2022 | 95 | 0.050 |
Why?
| Complement Activation | 1 | 2021 | 43 | 0.050 |
Why?
| Patient Acuity | 1 | 2021 | 16 | 0.050 |
Why?
| Enzyme Inhibitors | 1 | 2004 | 446 | 0.050 |
Why?
| Injury Severity Score | 1 | 2021 | 178 | 0.050 |
Why?
| Dopamine | 1 | 2022 | 190 | 0.050 |
Why?
| Influenza in Birds | 1 | 2020 | 5 | 0.050 |
Why?
| Birds | 1 | 2020 | 13 | 0.050 |
Why?
| Recurrence | 2 | 2012 | 690 | 0.050 |
Why?
| Blood Gas Analysis | 1 | 2020 | 32 | 0.050 |
Why?
| DNA, Bacterial | 1 | 2021 | 172 | 0.050 |
Why?
| Calcium | 1 | 2022 | 432 | 0.050 |
Why?
| Single-Cell Analysis | 1 | 2020 | 56 | 0.050 |
Why?
| Stromal Cells | 1 | 2020 | 79 | 0.050 |
Why?
| Bicarbonates | 1 | 2020 | 21 | 0.050 |
Why?
| Endpoint Determination | 1 | 2020 | 30 | 0.050 |
Why?
| Seasons | 1 | 2020 | 98 | 0.050 |
Why?
| American Heart Association | 1 | 2020 | 36 | 0.050 |
Why?
| Extracellular Matrix | 1 | 2020 | 111 | 0.050 |
Why?
| Community-Acquired Infections | 1 | 2020 | 42 | 0.050 |
Why?
| Developmental Disabilities | 1 | 2021 | 127 | 0.050 |
Why?
| Interferon-alpha | 1 | 2020 | 50 | 0.050 |
Why?
| Regression Analysis | 1 | 2021 | 445 | 0.050 |
Why?
| Maternal Exposure | 2 | 2012 | 87 | 0.050 |
Why?
| Cells, Cultured | 1 | 2004 | 1737 | 0.040 |
Why?
| Hematoma, Subdural | 1 | 2019 | 27 | 0.040 |
Why?
| Consensus | 1 | 2020 | 157 | 0.040 |
Why?
| Bayes Theorem | 1 | 2020 | 123 | 0.040 |
Why?
| Rats | 2 | 2004 | 3415 | 0.040 |
Why?
| Pilot Projects | 1 | 2022 | 808 | 0.040 |
Why?
| Skull Fractures | 1 | 2019 | 25 | 0.040 |
Why?
| Cardiac Output | 1 | 2019 | 50 | 0.040 |
Why?
| Intracranial Hemorrhages | 1 | 2019 | 41 | 0.040 |
Why?
| Mortality | 1 | 2020 | 102 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2020 | 125 | 0.040 |
Why?
| Amino Acid Substitution | 1 | 2019 | 105 | 0.040 |
Why?
| Data Collection | 1 | 2020 | 321 | 0.040 |
Why?
| Creatinine | 1 | 2019 | 169 | 0.040 |
Why?
| Family | 1 | 2020 | 193 | 0.040 |
Why?
| Metabolic Clearance Rate | 1 | 2019 | 75 | 0.040 |
Why?
| Communication | 1 | 2021 | 273 | 0.040 |
Why?
| Adaptation, Psychological | 1 | 2020 | 244 | 0.040 |
Why?
| RNA, Messenger | 1 | 2022 | 1202 | 0.040 |
Why?
| Inflammation | 1 | 2023 | 674 | 0.040 |
Why?
| Staphylococcus aureus | 1 | 2022 | 361 | 0.040 |
Why?
| Antiviral Agents | 1 | 2020 | 188 | 0.040 |
Why?
| Gene Expression Profiling | 2 | 2020 | 1138 | 0.040 |
Why?
| Feasibility Studies | 1 | 2019 | 398 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2018 | 91 | 0.040 |
Why?
| Glucocorticoids | 1 | 2020 | 234 | 0.040 |
Why?
| Comorbidity | 1 | 2020 | 663 | 0.040 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2020 | 434 | 0.040 |
Why?
| Causality | 1 | 2017 | 46 | 0.040 |
Why?
| Genotyping Techniques | 1 | 2017 | 26 | 0.040 |
Why?
| Aged | 2 | 2022 | 10054 | 0.040 |
Why?
| Point-of-Care Systems | 1 | 2018 | 70 | 0.040 |
Why?
| Homozygote | 1 | 2017 | 60 | 0.040 |
Why?
| Proteins | 1 | 2000 | 376 | 0.040 |
Why?
| Social Class | 1 | 2018 | 110 | 0.040 |
Why?
| Pandemics | 1 | 2022 | 579 | 0.040 |
Why?
| Protein Isoforms | 1 | 2017 | 124 | 0.040 |
Why?
| Linear Models | 1 | 2018 | 309 | 0.040 |
Why?
| Diagnosis, Differential | 1 | 2021 | 1136 | 0.040 |
Why?
| Protein Binding | 1 | 2019 | 736 | 0.040 |
Why?
| Body Weight | 1 | 2019 | 578 | 0.040 |
Why?
| Depression | 1 | 2021 | 595 | 0.030 |
Why?
| National Institutes of Health (U.S.) | 1 | 2016 | 49 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2018 | 1048 | 0.030 |
Why?
| Algorithms | 1 | 2019 | 697 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2018 | 596 | 0.030 |
Why?
| Models, Biological | 1 | 2019 | 823 | 0.030 |
Why?
| Potassium | 1 | 2014 | 60 | 0.030 |
Why?
| Child Health Services | 1 | 2016 | 98 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 684 | 0.030 |
Why?
| Orthomyxoviridae | 1 | 2014 | 6 | 0.030 |
Why?
| Immune System | 1 | 2013 | 49 | 0.030 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 53 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 913 | 0.030 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2014 | 202 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2012 | 133 | 0.030 |
Why?
| Diagnostic Imaging | 1 | 2012 | 184 | 0.020 |
Why?
| Electrocardiography | 1 | 2012 | 290 | 0.020 |
Why?
| Endothelial Cells | 1 | 2012 | 294 | 0.020 |
Why?
| Dietary Supplements | 1 | 2013 | 449 | 0.020 |
Why?
| Mice | 1 | 2020 | 6413 | 0.020 |
Why?
| Flow Cytometry | 1 | 2012 | 546 | 0.020 |
Why?
| Middle Aged | 1 | 2020 | 13088 | 0.020 |
Why?
| Embryo, Mammalian | 1 | 2000 | 68 | 0.010 |
Why?
| Cloning, Molecular | 1 | 2000 | 198 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|